New onset executive function difficulties at menopause: a possible role for lisdexamfetamine.

摘要: Reports of cognitive decline, particularly in the domains executive functions (EFs), are common among menopausal women. This study aims to determine impact psychostimulant lisdexamfetamine (LDX) on subjective and objective function women who report new-onset EF complaints. Thirty-two healthy perimenopausal early postmenopausal experiencing mid-life-onset difficulties as measured using Brown Attention Deficit Disorder Scale (BADDS) were administered LDX 40–60 mg/day for 4 weeks this double-blind, placebo-controlled, cross-over study. Diagnosis lifetime ADHD was exclusionary. BADDS total subscale scores performance verbal memory working tasks outcomes interest. Analyses revealed a significant effect treatment over placebo (p = 0.0001) four out five subscales (all p < 0.004). also resulted improvement delayed paragraph recall (p = 0.018), but there no other measures. Systolic blood pressure (p = 0.017) heart rate increased significantly (p = 0.006) when remained, average, within normal range. well tolerated improved measures sample